Health Care Innovation
Blog
Despite High Costs, Americans Support Potential of Innovative Gene Therapies to Cure Difficult-to-Treat Diseases
SAN FRANCISCO – A new poll from the California-based nonpartisan think tank, the Pacific Research Institute (PRI), shows that Americans overwhelmingly support innovative gene therapies, which change the focus of medicine from treating illnesses to curing illnesses. Click here to read the top-line results of PRI’s poll on gene therapies ...
Pacific Research Institute
June 26, 2019
Health Care
Much-Publicized Report on Financial Returns on Cancer Treatments Contains Significant Flaws and Biases, Finds New PRI Brief
The World Health Organization (WHO) is advocating that the prices of cancer treatments are excessive, but its report that justifies this conclusion contains significant biases that drastically over-estimates the revenues multiple over research and development (R&D) costs, according to a new issue brief released today by the Center for Medical ...
Wayne H Winegarden
June 12, 2019
Commentary
How socialist price controls will harm American patients
The Trump administration is planning to propose one of the biggest changes to Medicare in decades. The draft rule aims to reduce government spending by linking Medicare drug reimbursement rates to the rates in more than a dozen other Western countries that use price controls to hold down pharmaceutical spending. If implemented, ...
Sally C. Pipes
June 11, 2019
Commentary
Don’t Legislate Away Biopharmaceutical Innovation
The U.S. economy thrives on innovation. According to the U.S. Patent and Trademark Office, industries that intensively rely on intellectual property (IP) protections, which includes the biopharmaceutical industry, account for nearly 40 percent of the U.S. economy and are responsible for an outsized share of our overall economic growth. Beyond the ...
Wayne Winegarden
May 30, 2019
Blog
“HELP-ing” to Make Health Care More Affordable
The Senate Health, Education, Labor & Pensions (HELP) Committee has just released a bi-partisan bill authored by Senators Lamar Alexander (R-TN) and Patty Murray (D-WA) that would make health care more affordable and more transparent for patients. These reforms are not grandiose fantasies that are destined to fail, such as ...
Wayne Winegarden
May 29, 2019
Commentary
Differentiating Health Care Costs from Health Care Value
The wrong model, no matter how hard you work it, will never provide the right answer. When it comes to how we pay for health care, the U.S. is using the wrong model. What’s worse, these financing inadequacies could threaten the viability of new therapies that will bring hope to ...
Wayne Winegarden
May 20, 2019
Health Care
Read Sally Pipes in Heartland News Story on Telemedicine
Telemedicine Offers Remedy for Rising Travel and Wait Times By Leo Pusateri Travel and wait times for health care cost patients $89 billion annually, according to an analysis by Altarum, giving new vigor to legislative arguments supporting telemedicine. Patients travel an average of 34 minutes for health care and wait ...
Pacific Research Institute
May 17, 2019
California
The Perils of Regulating Drugs by Sound Bite
There is a legal adage that “hard cases make bad law.” California may soon rediscover this wisdom. Assembly member Jim Wood has introduced a bill (AB 824) with the intention of discouraging “pay-for-delay” tactics. “Pay-for-delay” practices refer to a situation when a manufacturer of a patented drug pays the manufacturer ...
Wayne Winegarden
May 16, 2019
Commentary
Price Controls by Another Name
The costs of medicines continue to dominate the headlines, attracting the attention of Congress and the Trump Administration. Reforms are necessary, but many of the reforms under consideration will make the situation worse. Indexing U.S. prices to the prices in other countries that use price controls, or using third-party arbitration ...
Wayne Winegarden
April 30, 2019
Agriculture
The Brave Old World of Genetic Engineering
By Henry I. Miller, M.S., M.D. and Rob Wager A Washington Post article, “The Future of Food,” discussed the methods we use to breed food crops but suffered from a shortcoming we see often: “pseudo-balance” — the seeking out of clueless commentators to contradict advocates of superior modern genetic modification ...
Pacific Research Institute
April 30, 2019
Despite High Costs, Americans Support Potential of Innovative Gene Therapies to Cure Difficult-to-Treat Diseases
SAN FRANCISCO – A new poll from the California-based nonpartisan think tank, the Pacific Research Institute (PRI), shows that Americans overwhelmingly support innovative gene therapies, which change the focus of medicine from treating illnesses to curing illnesses. Click here to read the top-line results of PRI’s poll on gene therapies ...
Much-Publicized Report on Financial Returns on Cancer Treatments Contains Significant Flaws and Biases, Finds New PRI Brief
The World Health Organization (WHO) is advocating that the prices of cancer treatments are excessive, but its report that justifies this conclusion contains significant biases that drastically over-estimates the revenues multiple over research and development (R&D) costs, according to a new issue brief released today by the Center for Medical ...
How socialist price controls will harm American patients
The Trump administration is planning to propose one of the biggest changes to Medicare in decades. The draft rule aims to reduce government spending by linking Medicare drug reimbursement rates to the rates in more than a dozen other Western countries that use price controls to hold down pharmaceutical spending. If implemented, ...
Don’t Legislate Away Biopharmaceutical Innovation
The U.S. economy thrives on innovation. According to the U.S. Patent and Trademark Office, industries that intensively rely on intellectual property (IP) protections, which includes the biopharmaceutical industry, account for nearly 40 percent of the U.S. economy and are responsible for an outsized share of our overall economic growth. Beyond the ...
“HELP-ing” to Make Health Care More Affordable
The Senate Health, Education, Labor & Pensions (HELP) Committee has just released a bi-partisan bill authored by Senators Lamar Alexander (R-TN) and Patty Murray (D-WA) that would make health care more affordable and more transparent for patients. These reforms are not grandiose fantasies that are destined to fail, such as ...
Differentiating Health Care Costs from Health Care Value
The wrong model, no matter how hard you work it, will never provide the right answer. When it comes to how we pay for health care, the U.S. is using the wrong model. What’s worse, these financing inadequacies could threaten the viability of new therapies that will bring hope to ...
Read Sally Pipes in Heartland News Story on Telemedicine
Telemedicine Offers Remedy for Rising Travel and Wait Times By Leo Pusateri Travel and wait times for health care cost patients $89 billion annually, according to an analysis by Altarum, giving new vigor to legislative arguments supporting telemedicine. Patients travel an average of 34 minutes for health care and wait ...
The Perils of Regulating Drugs by Sound Bite
There is a legal adage that “hard cases make bad law.” California may soon rediscover this wisdom. Assembly member Jim Wood has introduced a bill (AB 824) with the intention of discouraging “pay-for-delay” tactics. “Pay-for-delay” practices refer to a situation when a manufacturer of a patented drug pays the manufacturer ...
Price Controls by Another Name
The costs of medicines continue to dominate the headlines, attracting the attention of Congress and the Trump Administration. Reforms are necessary, but many of the reforms under consideration will make the situation worse. Indexing U.S. prices to the prices in other countries that use price controls, or using third-party arbitration ...
The Brave Old World of Genetic Engineering
By Henry I. Miller, M.S., M.D. and Rob Wager A Washington Post article, “The Future of Food,” discussed the methods we use to breed food crops but suffered from a shortcoming we see often: “pseudo-balance” — the seeking out of clueless commentators to contradict advocates of superior modern genetic modification ...